Abstract
Data on perioperative chemotherapy (CTX) in resectable pancreatic cancer (rPDAC) are limited. The NEONAX trial examined perioperative or adjuvant CTX with gemcitabine plus nab-paclitaxel in rPDAC (NCCN criteria).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
